Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study

Overview of attention for article published in Journal of Clinical Oncology, June 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 5 news outlets
blogs: 1 blog

twitter: 23 X users

Readers on

mendeley: 25 Mendeley

So far, Altmetric has seen 5 news stories from 5 outlets.

Taxane Maintenance Improves PFS, Not OS in Ovarian Cancer

Cancer Therapy Advisor, 12 Jul 2022

Maintenance therapy with paclitaxel or paclitaxel poliglumex (PP) does not improve overall survival (OS), when compared with…

OS Not Improved, Modest PFS Benefit Noted Following Chemo Maintenance in Newly Diagnosed Advanced Ovarian Cancer

Cancer Network, 08 Jul 2022

Patients with advanced newly diagnosed ovarian, tubal, or peritoneal cancer did not derive further survival benefit from…

Additional taxane maintenance therapy does not successfully improve overall survival for women with advanced ovarian, peritoneal, and tubal cancers - ecancer

ecancer, 29 Jun 2022

Results from the NRG Oncology phase III clinical trial NRG GOG-0212 indicated that treating women who received complete…

Additional taxane maintenance therapy does not successfully improve overall survival for women with advanced ovarian, peritoneal, and tubal cancers

EurekAlert!, 28 Jun 2022

Results from the NRG Oncology phase III clinical trial NRG GOG-0212 indicated that treating women who received complete…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.